Clinical Study of First-line Treatment of Small Cell Lung Cancer (SCLC) With Anlotinib Hydrochloride

• Status: Unknown status
• Trial end date: 2020-10-01

Summary

This study was designed to investigate the efficacy and side effects of combining erlotinib with classical EC/EP chemotherapy regimens.

• Phase: Phase 4

Details

• Lead Sponsor: Chifeng Municipal Hospital